VirtualScopics (VSCP) 10-Q 14 Nov 13 2013 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Sep. 30, 2013	Oct. 31, 2013
Document Information [Line Items]	'	'
Entity Registrant Name	'VirtualScopics, Inc.	'
Entity Central Index Key	'0001307752	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Trading Symbol	'VSCP	'
Entity Common Stock, Shares Outstanding	'	2,979,952
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-13	'
Document Fiscal Period Focus	'Q3	'
Document Fiscal Year Focus	'2013	'

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Sep. 30, 2013	Dec. 31, 2012
Assets	'	'
Cash	$7,003,656	$8,523,807
Accounts receivable, net	2,264,488	1,762,507
Prepaid expenses and other current assets	420,572	437,698
Total current assets	9,688,716	10,724,012
Patents, net	1,364,688	1,470,436
Property and equipment, net	226,530	399,569
Other assets	0	5,428
Total assets	11,279,934	12,599,445
Liabilities and Stockholders' Equity	'	'
Accounts payable and accrued expenses	673,131	872,652
Accrued payroll	569,309	481,661
Unearned revenue	505,543	272,509
Dividends payable	251,333	125,333
Total current liabilities	1,999,316	1,752,155
Commitments and Contingencies	'	'
Stockholders' Equity	'	'
Common stock, $0.001 par value; 85,000,000 shares authorized; issued 2,992,928 and 2,979,952 shares at September 30, 2013 and December 31, 2012, respectively; outstanding, 2,979,952 shares at September 30, 2013 and December 31, 2012, respectively	2,980	2,980
Additional paid-in capital	21,971,215	21,807,904
Accumulated deficit	-12,693,583	-10,963,600
Total stockholders' equity	9,280,618	10,847,290
Total liabilities and stockholders' equity	11,279,934	12,599,445
Convertible Preferred Stock Series A [Member]	'	'
Stockholders' Equity	'	'
Convertible preferred stock	2	2
Convertible Preferred Stock Series B [Member]	'	'
Stockholders' Equity	'	'
Convertible preferred stock	1	1
Convertible Preferred Stock Series C - 1 [Member]	'	'
Stockholders' Equity	'	'
Convertible preferred stock	3	3
Convertible Preferred Stock Series C - 2 [Member]	'	'
Stockholders' Equity	'	'
Convertible preferred stock	$0	$0

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets [Parenthetical] (USD $)	Sep. 30, 2013	Dec. 31, 2012
Convertible preferred stock, par value (in dollars per share)	$0.00	$0.00
Convertible preferred stock, shares authorized	15,000,000	15,000,000
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	85,000,000	85,000,000
Common stock, shares Issued	2,992,928	2,979,952
Common stock, shares outstanding	2,979,952	2,979,952
Convertible Preferred Stock Series A [Member]	'	'
Convertible preferred stock, shares authorized	8,400	8,400
Convertible preferred stock, shares issued	2,190	2,190
Convertible preferred stock, shares outstanding	2,190	2,190
Convertible preferred stock, liquidation preference (in dollars per share)	$1,000	$1,000
Convertible Preferred Stock Series B [Member]	'	'
Convertible preferred stock, shares authorized	6,000	6,000
Convertible preferred stock, shares issued	600	600
Convertible preferred stock, shares outstanding	600	600
Convertible preferred stock, liquidation preference (in dollars per share)	$1,000	$1,000
Convertible Preferred Stock Series C - 1 [Member]	'	'
Convertible preferred stock, shares authorized	3,000	3,000
Convertible preferred stock, shares issued	3,000	3,000
Convertible preferred stock, shares outstanding	3,000	3,000
Convertible preferred stock, liquidation preference (in dollars per share)	$1,000	$1,000
Convertible Preferred Stock Series C - 2 [Member]	'	'
Convertible preferred stock, shares authorized	3,000	3,000
Convertible preferred stock, shares issued	0	0
Convertible preferred stock, shares outstanding	0	0
Convertible preferred stock, liquidation preference (in dollars per share)	$1,000	$1,000

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenues	$2,144,535	$3,095,080	$7,973,973	$9,487,055
Reimbursement revenues	83,342	233,137	493,168	879,181
Total revenues	2,227,877	3,328,217	8,467,141	10,366,236
Cost of services	1,328,406	1,633,024	4,602,469	5,270,148
Cost of reimbursement revenues	83,342	233,137	493,168	879,181
Total cost of services	1,411,748	1,866,161	5,095,637	6,149,329
Gross profit	816,129	1,462,056	3,371,504	4,216,907
Operating expenses	'	'	'	'
Research and development	376,595	414,913	1,179,760	1,171,589
Sales and marketing	347,977	314,991	1,135,782	961,714
General and administrative	747,708	684,052	2,511,330	2,202,368
Depreciation and amortization	88,863	101,393	275,730	320,003
Total operating expenses	1,561,143	1,515,349	5,102,602	4,655,674
Operating loss	-745,014	-53,293	-1,731,098	-438,767
Other income (expense)	'	'	'	'
Other income	1,030	1,044	5,381	2,174
Other expense	-6,680	-7,206	-17,561	-12,920
Unrealized (loss) gain on change in fair value of the derivative liabilities	-658	-19,794	13,295	-306,247
Total other (expense) income	-6,308	-25,956	1,115	-316,993
Net loss	-751,322	-79,249	-1,729,983	-755,760
Preferred stock deemed dividend	0	0	0	1,806,919
Preferred stock dividends	42,000	42,000	126,000	95,333
Net loss available to common stockholders	($793,322)	($121,249)	($1,855,983)	($2,658,012)
Weighted average basic and diluted shares Outstanding (in shares)	2,979,952	2,974,776	2,979,952	2,960,868
Basic and diluted loss per share (in dollars per share)	($0.27)	($0.04)	($0.62)	($0.90)

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Cash flows from operating activities	'	'
Net loss	($1,729,983)	($755,760)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	275,730	320,003
Loss on the disposal of assets	10,098	0
Stock-based compensation	289,311	465,888
Fair value adjustment of derivative liabilities	-13,295	306,247
Changes in operating assets and liabilities	'	'
Accounts receivable	-501,981	-293,167
Prepaid expenses and other assets	22,554	-28,778
Accounts payable and accrued expenses	-186,226	-21,471
Accrued payroll	87,648	-285,371
Unearned revenue	233,034	-181,220
Total adjustments	216,873	282,131
Net cash used in operating activities	-1,513,110	-473,629
Cash flows from investing activities	'	'
Purchases of property and equipment	-26,640	-123,157
Proceeds from the sale of equipment	28,441	0
Acquisition of patents	-8,842	-16,576
Net cash used in investing activities	-7,041	-139,733
Cash flows from financing activities	'	'
Proceeds from the exercise of warrants	0	262,500
Proceeds from the exercise of stock options	0	20,200
Proceeds from the issuance of series C-1 preferred stock and warrant, net of issuance costs	0	2,666,485
Cash dividends on series B preferred stock	0	-12,000
Net cash provided by financing activities	0	2,937,185
Net (decrease) increase in cash	-1,520,151	2,323,823
Cash	'	'
Beginning of period	8,523,807	5,737,009
End of period	7,003,656	8,060,832
Non-cash financing activity:	'	'
Accrued dividends on series B and C-1 preferred stock	251,333	83,333
Reclassification of derivative liabilities to additional paid in capital in connection with the series C-1 preferred stock issuance	$0	$405,233

Nature_of_Business_and_Basis_o

Nature of Business and Basis of Presentation	9 Months Ended
	Sep. 30, 2013
Organization and Basis Of Presentation [Abstract]	'
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	'
	NOTE 1 - Nature of Business and Basis of Presentation
	Nature of Business
	The Company’s headquarters are located in Rochester, New York. The Company has created a suite of image analysis software tools and applications which are used in detecting and measuring specific anatomical structures and metabolic activity using medical images. The Company’s developed proprietary software provides measurement capabilities designed to improve pharmaceutical and medical device research and development and improve clinical medical image analysis.
	Basis of Presentation
	The accompanying unaudited condensed consolidated financial statements of the Company have been condensed in certain respects and should, therefore, be read in conjunction with the audited consolidated financial statements and notes related thereto contained in the Company’s Annual Report on Form 10-K as of and for the year ended December 31, 2012. In the opinion of management, these financial statements contain all adjustments necessary for a fair presentation for the interim period, all of which were normal recurring adjustments. The results of operations for the three and nine months ended September 30, 2013 are not necessarily indicative of the results to be expected for the full year ending December 31, 2013.
	A Certificate of Amendment to effect a reverse stock split was approved by the Company's stockholders at its Annual Meeting of Stockholders held on August 13, 2013.  The Company's stockholders granted the Board authority to effectuate a reverse stock split at a ratio of between 1-for-2 to 1-for-10. The Company’s Board of Directors subsequently approved a 1-for-10 reverse stock split of the Company’s outstanding common stock that was effected on August 21, 2013. Corresponding adjustments were made to the number of shares of common stock underlying the Company’s outstanding options, warrants, and preferred stock exercisable for or convertible into common stock and the related long-term incentive plans for such options. All share and related option information presented in these financial statements and accompanying footnotes have been retroactively adjusted to reflect the reduced number of shares resulting from this action.
	On August 29, 2012, the Company received written notice from the Nasdaq Stock Market (“Nasdaq”) that the Company was out of compliance with Rule 5550(a)(2) of the Nasdaq Marketplace rules, the minimum bid price requirements. Thereafter, Nasdaq granted the Company an extension until August 26, 2013 to regain compliance. On September 5, 2013, the closing price of the Company's common stock was $4.84 per share which marked the tenth consecutive day the stock price had a closing bid price above $1.00 per share resulting in the Company regaining compliance with Nasdaq.

Summary_of_Certain_Significant

Summary of Certain Significant Accounting Policies	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	NOTE 2 - Summary of Certain Significant Accounting Policies
	Principles of Consolidation
	The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, VirtualScopics, LLC. All significant intercompany balances and transactions have been eliminated in consolidation.
	Derivative Financial Instruments
	The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations. For stock-based derivative financial instruments, the Company uses the Black-Scholes option valuation model to value the derivative instruments at inception and on subsequent valuation dates. The warrants issued with the Company’s Series B preferred stock, and to the placement agent in the Series B financing, did not have fixed settlement provisions because their exercise prices may be lowered if the Company issues securities at lower prices in the future. The Company was required to include the reset provisions in order to protect the warrant holders from the potential dilution associated with future financings. Accordingly, the warrants are recognized as a derivative instrument.
	Revenue Recognition
	The Company recognizes revenue when it is realized or realizable and earned. The Company considers revenue realized or realizable and earned when an agreement exists, services and products have been performed, prices are fixed or determinable, and collectability is reasonably assured. Revenues are reduced for estimated discounts and other allowances, if any.
	The Company provides advanced medical image analysis on a per analysis basis, and recognizes revenue when the image analysis is completed. Revenue related to project, data and site management services is recognized as the services are rendered and in accordance with the terms of the contract. Consulting revenue is recognized once the services are rendered and typically charged as an hourly rate.
	Occasionally, the Company has provided software development services to its customers, which may require development, modification, and customization. Software development revenue is billed on a fixed price basis and recognized upon delivery of the software and acceptance by the customer on a completed contract basis. The Company does not sell software licenses, upgrades or enhancements, or post-contract customer services.
	Reimbursements received and related costs incurred for out-of-pocket expenses are separately reported as revenue and cost of services, respectively, in the financial statements.
	Income Taxes
	Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income and the reversal of deferred tax liabilities during the period in which related temporary differences become deductible. The benefit of tax positions taken or expected to be taken in the Company’s income tax returns are recognized in the consolidated financial statements if such positions are more likely than not of being sustained.
	The Financial Accounting Standards Board (“FASB”) has issued Accounting Standards Update (“ASU”) No. 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (a consensus of the FASB Emerging Issues Task Force). The amendments in this ASU state that an unrecognized tax benefit, or a portion of an unrecognized tax benefit, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, except as follows. To the extent a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction to settle any additional income taxes that would result from the disallowance of a tax position or the tax law of the applicable jurisdiction does not require the entity to use, and the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be combined with deferred tax assets. The amendments in this ASU are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. For nonpublic entities, the amendments are effective for fiscal years, and interim periods within those years, beginning after December 15, 2014. Early adoption is permitted. The amendments should be applied prospectively to all unrecognized tax benefits that exist at the effective date. Retrospective application is permitted. The adoption of this standard is not expected to have a material impact on the Company’s condensed consolidated financial position and results of operations.
	Research and Development
	Research and development expense relates to the development of new applications and processes including improvements and enhancements to existing software applications. These costs are expensed as incurred.
	Fair Value of Financial Instruments
	Fair value of financial instruments is defined as an exit price, which is the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date. The degree of judgment utilized in measuring the fair value of assets and liabilities generally correlates to the level of pricing observability. Financial assets and liabilities with readily available, actively quoted prices or for which fair value can be measured from actively quoted prices in active markets generally have more pricing observability and require less judgment in measuring fair value. Conversely, financial assets and liabilities that are rarely traded or not quoted have less price observability and are generally measured at fair value using valuation models that require more judgment. These valuation techniques involve some level of management estimation and judgment, the degree of which is dependent on the price transparency of the asset, liability or market and the nature of the asset or liability. The Company has categorized its financial assets and liabilities measured at fair value into a three-level hierarchy.
	Preferred Stock
	The Company applies the accounting standards for distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. Conditionally redeemable preferred shares (including preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, preferred shares are classified as stockholders’ equity.
	Convertible Instruments
	The Company applies the accounting standards for derivatives and hedging and for distinguishing liabilities from equity when accounting for hybrid contracts that feature conversion options. The accounting standards require companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (i) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (ii) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (iii) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. The derivative is subsequently marked to market at each reporting date based on current fair value, with the changes in fair value reported in results of operations.
	Conversion options that contain variable settlement features such as provisions to adjust the conversion price upon subsequent issuances of equity or equity linked securities at exercise prices more favorable than that featured in the hybrid contract generally result in their bifurcation from the host instrument.
	The Company accounts for convertible debt instruments when the Company has determined that the embedded conversion options should not be bifurcated from their host instruments in accordance with Accounting Standards Codification (“ASC”) 470-20 “Debt with Conversion and Other Options”. The Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt. The Company also records, when necessary, deemed dividends for the intrinsic value of the conversion options embedded in preferred stock based upon the difference between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the preferred stock.
	Common Stock Purchase Warrants and Other Derivative Financial Instruments
	The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) provides a choice of net-cash settlement or settlement in the Company’s own shares (physical settlement or net-share settlement) providing that such contracts are indexed to the Company's own stock as defined in ASC 815-40 "Contracts in Entity's Own Equity" (“ASC 815-40”). The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control) or (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement).  The Company assesses classification of common stock purchase warrants and other free standing derivatives at each reporting date to determine whether a change in classification between assets and liabilities or equity is required.

StockBased_Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2013
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	NOTE 3 - Stock-Based Compensation
	For the three and nine months ended September 30, 2013 and 2012, the Company’s condensed consolidated statements of operations reflect stock-based compensation expense for stock options granted under its long-term incentive plans and allocated as follows:
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013		2012
	Cost of service revenues	$	12,909		$	18,039		$	38,123	$	44,796
	Research and development		12,392			17,110			48,288		59,622
	Sales and marketing		2,789			2,851			8,612		7,109
	General and administrative		1,487			105,945			174,509		346,236
	Total stock-based compensation	$	29,577		$	143,945		$	269,532	$	457,763
	Stock options issued under the Company’s long-term incentive plans are granted with an exercise price equal to no less than the market price of the Company’s stock at the date of grant and expire up to ten years from the date of grant. These options generally vest over a three or four-year period.
	The fair value of stock options granted was determined on the grant date using assumptions for risk free interest rate, the expected term, expected volatility, and expected dividend yield. The risk free interest rate is based on U.S. Treasury zero-coupon yield curve over the expected term of the option. The expected term assumption is determined using the weighted average midpoint between the vesting and expiration term for all individuals within the grant. Through the second quarter of 2012, the Company had estimated its expected volatility from an index of historical stock prices of comparable entities whose share prices were publicly traded and averaged with the Company’s historical stock prices, excluding the first ten months due to the discreet and non-recurring nature of the trading. Beginning in the third quarter of 2012, the Company estimated its expected volatility using only its own historical stock prices, continuing to exclude the first ten months due to the discreet and non-recurring nature of the trading, as management determined this assumption to be a better indicator of value at this time. The Company’s model includes a zero dividend yield assumption, as the Company has not historically paid nor does it anticipate paying dividends on its common stock. The Company’s model does not include a discount for post-vesting restrictions, as the Company has not issued awards with such restrictions. The periodic expense is then determined based on the valuation of the options, and at that time an estimated forfeiture rate is used to reduce the expense recorded. The Company’s estimate of pre-vesting forfeitures is primarily based on the Company’s historical experience and is adjusted to reflect actual forfeitures as the options vest. The estimated forfeiture rates used during the nine months ended September 30, 2013 and 2012 ranged from 7.2% to 7.5%. The following assumptions were used to estimate the fair value of options granted for the nine months ended September 30, 2013 and 2012 using the Black-Scholes option-pricing model:
		September 30,
		2013				2012
	Risk free interest rate		1.5	%			1.1	%
	Expected term (years)		6.6				6.3
	Expected volatility		71.3	%			57.6	%
	Expected dividend yield		-				-
	A summary of the employee stock option activity for the nine months ended September 30, 2013 is as follows:
								Weighted
								Average
					Weighted			Remaining
		Number of			Average			Contractual
		Shares			Exercise Price			Term
	Options outstanding at January 1, 2013		597,504		$	13.03
	Granted		1,850			7.15
	Exercised		-
	Cancelled/Forfeited		-30,070			14.61
	Expired		-14,906			15.98
	Options outstanding at September 30, 2013		554,378			12.84			4.9
	Options exercisable at September 30, 2013		484,582			12.89			4.53
	The weighted-average grant-date fair value of options granted during the nine months ended September 30, 2013 and 2012 was $8,687 and $245,754, respectively.

Stockholders_Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2013
Stockholders Equity Note [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	NOTE 4 - Stockholders’ Equity
	On April 3, 2012, the Company and Merck Global Health Innovation Fund, LLC (“GHI”) entered into a Series C Preferred Stock and Warrant Purchase Agreement (the “Purchase Agreement”) under which the Company agreed to sell GHI up to 6,000 shares of the Company’s Series C Preferred Stock and warrants to purchase up to 272,263 shares of common stock at an exercise price of $12.043 per share (the “Series C Warrants”) for a purchase price of $6,000,000 in two separate closings.
	The initial closing under the Purchase Agreement took place on April 3, 2012 at which the Company sold to GHI 3,000 shares of Series C-1 Preferred Stock which were initially convertible into 249,107 shares of common stock and Series C-1 Warrants which were exercisable to purchase 136,132 shares of common stock for an aggregate purchase price of $3,000,000, net of issuance costs of approximately $334,000.
	The terms of the financing provided for a second closing of $3,000,000 of Series C-2 Preferred Stock, if, among other things, certain milestones are met toward the development of its quantitative imaging center on or before April 3, 2013. The second closing did not occur, however, the Company is continuing to pursue its efforts in this area, specifically, as it relates to obtaining FDA acceptance.
	As of September 30, 2013, dividends payable to Series B and C-1 convertible preferred stockholders amounted to $72,000 and $179,333, respectively and are included in dividends payable on the Company’s condensed consolidated balance sheet.
	Restricted Stock Awards
	A restricted stock award entitles the recipient to receive shares of unrestricted common stock upon vesting of the award and expiration of the restrictions. The fair value of each restricted stock award is determined upon granting of the shares and the related compensation expense is recognized ratably over the vesting period and charged to the operations as non-cash compensation expense. Shares contained in the unvested portion of restricted stock awards are forfeited upon termination of employment, unless otherwise agreed. The fair value of restricted stock issued under the Plan is determined based on the closing price of the Company’s common stock on the grant date.
	A summary of the restricted stock award activity for the nine months ended September 30, 2013 is as follows:
				Weighted
				Average
				Grant
		Number		Date Fair
		of Units		Value
	Nonvested at January 1, 2013		-
	Granted		15,927		7.4
	Vested		-
	Cancelled/Forfeited		-2,951		7.4
	Nonvested at September 30, 2013		12,976		7.4
	The Company incurred $19,779 and $8,125 in compensation expense during the nine months ended September 30, 2013 and 2012, respectively, and $7,427 and $0 in compensation expense during the three ended September 30, 2013 and 2012, respectively, related to the restricted stock awards granted to Board members and Company officers. During the first nine months of 2013, the Company issued an aggregate 15,927 restricted stock awards to the CEO and CFO having a grant date fair value of $117,861 ($7.40 per unit) and vest over a four year period. On August 31, 2013, 2,951 restricted stock awards were forfeited as the result of the resignation of the former CFO.

Derivative_Liabilities

Derivative Liabilities	9 Months Ended
	Sep. 30, 2013
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Derivative Instruments and Hedging Activities Disclosure [Text Block]	'
	NOTE 5 - Derivative Liabilities
	Derivative liabilities resulting from certain warrants issued in connection with the Company’s Series B financing were valued using the Black-Scholes option valuation model and the following assumptions on the following dates:
		September 30,			December 31,
		2013			2012
	Series B warrants:
	Risk-free interest rate		0.1	%		0.22	%
	Expected volatility		62.28	%		65.94	%
	Expected life (in years)		0.94			1.69
	Expected dividend yield		-			-
	Number of warrants		21,423			21,423
	Fair value	$	2,655		$	15,950
	The risk-free interest rate was based on rates established by the Federal Reserve. The Company’s policy for expected volatility is disclosed in Note 3 Stock-Based Compensation. The expected life of the warrants was determined by the expiration date of the warrants. The expected dividend yield was based upon the fact that the Company has not historically paid dividends on its common stock, and does not expect to pay dividends on its common stock in the future. The warrants are considered to be level 3 financial liabilities in accordance with ASC 820 as there is no current market and determining the fair value requires significant judgment or estimation.
	The fair value of these warrant liabilities was $2,655 at September 30, 2013 as compared to $57,610 at September 30, 2012 and has been classified within accounts payable and accrued expenses on the accompanying condensed consolidated balance sheet. The net change in fair value during the first nine months of 2013 is $13,295, which was reported in the Company’s condensed consolidated statement of operations as an unrealized gain on the change in fair value of the derivative liabilities. The fair value of the derivative liabilities are re-measured at the end of every reporting period and upon the exercise of the warrant. The change in fair value is reported in the condensed consolidated statement of operations as an unrealized gain or loss on the change in fair value of the derivative liability. During the nine months ended September 30, 2013, there were no transfers in or out of Level 3.

Loss_Per_Share

Loss Per Share	9 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Earnings Per Share [Text Block]	'
	NOTE 6 – Loss Per Share
	Basic earnings and loss per share are computed by dividing the net income or loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options (using the treasury stock method) and the conversion of the Company’s convertible preferred stock and warrants (using the if-converted method). Diluted loss per share excludes the shares issuable upon the conversion of preferred stock, the exercise of stock options and warrants from the calculation of net loss per share as their effect would be antidilutive.
	Securities that could potentially dilute earnings per share in the future that were not included in the computation of diluted loss per share consist of the following numbers of shares into which preferred stock could have been converted and shares for which outstanding options and warrants could have been exercised during the three and nine months ending September 30, 2013 and 2012:
		2013		2012
	Convertible preferred stock		480,777		480,777
	Warrants to purchase common stock		233,753		242,534
	Non-vested restricted stock awards		12,976		-
	Options to purchase common stock		554,898		597,980
	Total		1,282,404		1,321,291

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	NOTE 7 - Income Taxes
	The Company has significant net operating loss and business credit carryovers which are subject to a valuation allowance due to the uncertain nature of the realization of the losses. The Internal Revenue Code imposes certain limitations on the utilization of net operating loss carryovers and other tax attributes after a change in control. The Company does not believe it has encountered ownership changes which could significantly limit the possible utilization of such carryovers. It is not anticipated that limitations, if any, would have a material impact on the condensed consolidated balance sheet as a result of offsetting changes in the deferred tax valuation allowance. Based on all available evidence, the Company believes that its deferred tax assets should be fully reserved as of September 30, 2013 because it is still currently more likely than not that the benefits of the Company’s deferred tax assets will not be realized in future periods. The Company will continue to assess the likelihood of recognizing a portion of its deferred tax assets and will make an assessment of whether it should reduce the valuation allowance.
	The Company will recognize interest and penalties accrued related to unrecognized tax benefits as components of its income tax provision. As of September 30, 2013, the Company does not have any interest and penalties accrued related to unrecognized tax benefits.

Concentration_of_Credit_Risk

Concentration of Credit Risk	9 Months Ended
	Sep. 30, 2013
Risks and Uncertainties [Abstract]	'
Concentration Risk Disclosure [Text Block]	'
	NOTE 8 - Concentration of Credit Risk
	The Company’s top three customers accounted for approximately 45%, 11%, and 11% of total revenue for the nine months ended September 30, 2013. Two customers accounted for 45% and 10% of total revenue for the nine months ended September 30, 2012.
	The Company’s top three customers accounted for approximately 36%, 16%, and 14% of total revenue for the three months ended September 30, 2013. Two customers accounted for 40% and 11% of total revenue for the three months ended September 30, 2012.
	Three customers accounted for approximately 53%, 15%, and 14% of accounts receivable as of September 30, 2013 as compared to the two customers accounting for 43% and 11% of accounts receivable as of September 30, 2012.

Related_Party

Related Party	9 Months Ended
	Sep. 30, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	NOTE 9 – Related Party
	In April 2012, the Company issued Merck Global Health Innovation Fund, LLC 3,000 shares of Series C-1 Preferred Stock which are convertible into 249,107 shares of common stock and Series C-1 Warrants which are exercisable to purchase 136,132 shares of common stock. Revenues generated from Merck were $164,171 and $966,190 for the nine months ended September 30, 2013 and 2012, respectively and $34,736 and $265,655 for the three months ended September 30, 2013 and 2012, respectively. The accounts receivable balance due from Merck was $20,532 and $96,096 as of September 30, 2013 and December 31, 2012, respectively.

Subsequent_Events

Subsequent Events	9 Months Ended
	Sep. 30, 2013
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	NOTE 10 - Subsequent Events
	On October 25, 2013, the Company entered into a Separation, Waiver and Release Agreement (the “Separation Agreement”) with its former Chief Executive Officer, L. Jeffrey Markin. Under the terms of the Separation Agreement, Mr. Markin will receive monthly separation payments in the amount of $25,310 commencing on the date of the Separation Agreement and continuing until May 31, 2014, In addition, he will receive benefits through May 31, 2014, on terms comparable to the benefits provided for under his existing Employment Agreement with the Company dated February 24, 2009, as amended by the Amendment to Employment Agreement, dated December 28, 2012 (as amended, the “Employment Agreement”). The Employment Agreement was terminated and superseded by the Separation Agreement. Mr. Markin will also receive the 2013 bonus earned under the Company’s Bonus Plan, pro-rated to the date of the Separation Agreement. Unvested stock options, stock awards and restricted stock units granted to Mr. Markin will be forfeited as of the effective date of the Separation Agreement, other than 11,992 shares underlying restricted stock units which vested on the date of termination. Also under the Separation Agreement, Mr. Markin provided a general release in favor of the Company and its affiliates. Mr. Markin is also obligated to comply with existing covenants not to compete, for nine months following the separation date, and of confidentiality.
	In connection with the resignation of the former CEO, the Company entered into a Services Agreement with Converse & Company, dated October 25, 2013 (the “Services Agreement”), pursuant to which Eric T. Converse, a principal and shareholder of Converse & Company, will serve as interim President and Chief Executive Officer of the Company. Mr. Converse is also a director of the Company. Mr. Converse will perform the duties and responsibilities as are customary for the President and Chief Executive Officer of a company and report to, and be subject to the supervision of, the Board of Directors of the Company.  Converse & Company’s fees are based upon a monthly rate of $25,310, for an initial term of 6 months, which may be extended by the Company on a month-to-month basis.   The Services Agreement may be terminated by either the Company or Converse & Company on notice to the other, provided that a minimum 6 month payment is due unless terminated for cause, as defined in the Services Agreement.

Summary_of_Certain_Significant1

Summary of Certain Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Consolidation, Policy [Policy Text Block]	'
	Principles of Consolidation
	The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, VirtualScopics, LLC. All significant intercompany balances and transactions have been eliminated in consolidation.
Derivatives, Policy [Policy Text Block]	'
	Derivative Financial Instruments
	The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations. For stock-based derivative financial instruments, the Company uses the Black-Scholes option valuation model to value the derivative instruments at inception and on subsequent valuation dates. The warrants issued with the Company’s Series B preferred stock, and to the placement agent in the Series B financing, did not have fixed settlement provisions because their exercise prices may be lowered if the Company issues securities at lower prices in the future. The Company was required to include the reset provisions in order to protect the warrant holders from the potential dilution associated with future financings. Accordingly, the warrants are recognized as a derivative instrument.
Revenue Recognition, Policy [Policy Text Block]	'
	Revenue Recognition
	The Company recognizes revenue when it is realized or realizable and earned. The Company considers revenue realized or realizable and earned when an agreement exists, services and products have been performed, prices are fixed or determinable, and collectability is reasonably assured. Revenues are reduced for estimated discounts and other allowances, if any.
	The Company provides advanced medical image analysis on a per analysis basis, and recognizes revenue when the image analysis is completed. Revenue related to project, data and site management services is recognized as the services are rendered and in accordance with the terms of the contract. Consulting revenue is recognized once the services are rendered and typically charged as an hourly rate.
	Occasionally, the Company has provided software development services to its customers, which may require development, modification, and customization. Software development revenue is billed on a fixed price basis and recognized upon delivery of the software and acceptance by the customer on a completed contract basis. The Company does not sell software licenses, upgrades or enhancements, or post-contract customer services.
	Reimbursements received and related costs incurred for out-of-pocket expenses are separately reported as revenue and cost of services, respectively, in the financial statements.
Income Tax, Policy [Policy Text Block]	'
	Income Taxes
	Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income and the reversal of deferred tax liabilities during the period in which related temporary differences become deductible. The benefit of tax positions taken or expected to be taken in the Company’s income tax returns are recognized in the consolidated financial statements if such positions are more likely than not of being sustained.
	The Financial Accounting Standards Board (“FASB”) has issued Accounting Standards Update (“ASU”) No. 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (a consensus of the FASB Emerging Issues Task Force). The amendments in this ASU state that an unrecognized tax benefit, or a portion of an unrecognized tax benefit, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, except as follows. To the extent a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction to settle any additional income taxes that would result from the disallowance of a tax position or the tax law of the applicable jurisdiction does not require the entity to use, and the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be combined with deferred tax assets. The amendments in this ASU are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. For nonpublic entities, the amendments are effective for fiscal years, and interim periods within those years, beginning after December 15, 2014. Early adoption is permitted. The amendments should be applied prospectively to all unrecognized tax benefits that exist at the effective date. Retrospective application is permitted. The adoption of this standard is not expected to have a material impact on the Company’s condensed consolidated financial position and results of operations.
Research and Development Expense, Policy [Policy Text Block]	'
	Research and Development
	Research and development expense relates to the development of new applications and processes including improvements and enhancements to existing software applications. These costs are expensed as incurred.
Fair Value of Financial Instruments, Policy [Policy Text Block]	'
	Fair Value of Financial Instruments
	Fair value of financial instruments is defined as an exit price, which is the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date. The degree of judgment utilized in measuring the fair value of assets and liabilities generally correlates to the level of pricing observability. Financial assets and liabilities with readily available, actively quoted prices or for which fair value can be measured from actively quoted prices in active markets generally have more pricing observability and require less judgment in measuring fair value. Conversely, financial assets and liabilities that are rarely traded or not quoted have less price observability and are generally measured at fair value using valuation models that require more judgment. These valuation techniques involve some level of management estimation and judgment, the degree of which is dependent on the price transparency of the asset, liability or market and the nature of the asset or liability. The Company has categorized its financial assets and liabilities measured at fair value into a three-level hierarchy.
Preferred Stock, Policy [Policy Text Block]	'
	Preferred Stock
	The Company applies the accounting standards for distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. Conditionally redeemable preferred shares (including preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, preferred shares are classified as stockholders’ equity.
Convertible Instruments, Policy [Policy Text Block]	'
	Convertible Instruments
	The Company applies the accounting standards for derivatives and hedging and for distinguishing liabilities from equity when accounting for hybrid contracts that feature conversion options. The accounting standards require companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (i) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (ii) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (iii) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. The derivative is subsequently marked to market at each reporting date based on current fair value, with the changes in fair value reported in results of operations.
	Conversion options that contain variable settlement features such as provisions to adjust the conversion price upon subsequent issuances of equity or equity linked securities at exercise prices more favorable than that featured in the hybrid contract generally result in their bifurcation from the host instrument.
	The Company accounts for convertible debt instruments when the Company has determined that the embedded conversion options should not be bifurcated from their host instruments in accordance with Accounting Standards Codification (“ASC”) 470-20 “Debt with Conversion and Other Options”. The Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt. The Company also records, when necessary, deemed dividends for the intrinsic value of the conversion options embedded in preferred stock based upon the difference between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the preferred stock.
Common Stock Purchase Warrants and Other Derivative Financial Instruments, Policy [Policy Text Block]	'
	Common Stock Purchase Warrants and Other Derivative Financial Instruments
	The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) provides a choice of net-cash settlement or settlement in the Company’s own shares (physical settlement or net-share settlement) providing that such contracts are indexed to the Company's own stock as defined in ASC 815-40 "Contracts in Entity's Own Equity" (“ASC 815-40”). The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control) or (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement).  The Company assesses classification of common stock purchase warrants and other free standing derivatives at each reporting date to determine whether a change in classification between assets and liabilities or equity is required.

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2013
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]	'
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	'
	For the three and nine months ended September 30, 2013 and 2012, the Company’s condensed consolidated statements of operations reflect stock-based compensation expense for stock options granted under its long-term incentive plans and allocated as follows:
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013		2012
	Cost of service revenues	$	12,909		$	18,039		$	38,123	$	44,796
	Research and development		12,392			17,110			48,288		59,622
	Sales and marketing		2,789			2,851			8,612		7,109
	General and administrative		1,487			105,945			174,509		346,236
	Total stock-based compensation	$	29,577		$	143,945		$	269,532	$	457,763
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
	The following assumptions were used to estimate the fair value of options granted for the nine months ended September 30, 2013 and 2012 using the Black-Scholes option-pricing model:
		September 30,
		2013				2012
	Risk free interest rate		1.5	%			1.1	%
	Expected term (years)		6.6				6.3
	Expected volatility		71.3	%			57.6	%
	Expected dividend yield		-				-
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	A summary of the employee stock option activity for the nine months ended September 30, 2013 is as follows:
								Weighted
								Average
					Weighted			Remaining
		Number of			Average			Contractual
		Shares			Exercise Price			Term
	Options outstanding at January 1, 2013		597,504		$	13.03
	Granted		1,850			7.15
	Exercised		-
	Cancelled/Forfeited		-30,070			14.61
	Expired		-14,906			15.98
	Options outstanding at September 30, 2013		554,378			12.84			4.9
	Options exercisable at September 30, 2013		484,582			12.89			4.53

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2013
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]	'
Schedule Of Share-Based Compensation, Non-Vested Stock Options, Activity [Table Text Block]	'
	A summary of the restricted stock award activity for the nine months ended September 30, 2013 is as follows:
				Weighted
				Average
				Grant
		Number		Date Fair
		of Units		Value
	Nonvested at January 1, 2013		-
	Granted		15,927		7.4
	Vested		-
	Cancelled/Forfeited		-2,951		7.4
	Nonvested at September 30, 2013		12,976		7.4

Derivative_Liabilities_Tables

Derivative Liabilities (Tables)	9 Months Ended
	Sep. 30, 2013
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Derivative Instruments, Valuation Assumptions [Table Text Block]	'
	Derivative liabilities resulting from certain warrants issued in connection with the Company’s Series B financing were valued using the Black-Scholes option valuation model and the following assumptions on the following dates:
		September 30,			December 31,
		2013			2012
	Series B warrants:
	Risk-free interest rate		0.1	%		0.22	%
	Expected volatility		62.28	%		65.94	%
	Expected life (in years)		0.94			1.69
	Expected dividend yield		-			-
	Number of warrants		21,423			21,423
	Fair value	$	2,655		$	15,950

Loss_Per_Share_Tables

Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	'
	Securities that could potentially dilute earnings per share in the future that were not included in the computation of diluted loss per share consist of the following numbers of shares into which preferred stock could have been converted and shares for which outstanding options and warrants could have been exercised during the three and nine months ending September 30, 2013 and 2012:
		2013		2012
	Convertible preferred stock		480,777		480,777
	Warrants to purchase common stock		233,753		242,534
	Non-vested restricted stock awards		12,976		-
	Options to purchase common stock		554,898		597,980
	Total		1,282,404		1,321,291

Nature_of_Business_and_Basis_o1

Nature of Business and Basis of Presentation (Details Textual) (USD $)	1 Months Ended
	Aug. 31, 2013	Sep. 05, 2013
Stockholders Equity, Reverse Stock Split	'1-for-10	'
Current Market Price	'	$4.84
Closing Bid Price	'	$1

StockBased_Compensation_Detail

Stock-Based Compensation (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Stock-based compensation	$29,577	$143,945	$269,532	$457,763
Cost of service revenues [Member]	'	'	'	'
Stock-based compensation	12,909	18,039	38,123	44,796
Research and development [Member]	'	'	'	'
Stock-based compensation	12,392	17,110	48,288	59,622
Sales and marketing [Member]	'	'	'	'
Stock-based compensation	2,789	2,851	8,612	7,109
General and administrative [Member]	'	'	'	'
Stock-based compensation	$1,487	$105,945	$174,509	$346,236

StockBased_Compensation_Detail1

Stock-Based Compensation (Details 1)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Risk free interest rate	1.50%	1.10%
Expected term (years)	'6 years 7 months 6 days	'6 years 3 months 18 days
Expected volatility	71.30%	57.60%
Expected dividend yield	0.00%	0.00%

StockBased_Compensation_Detail2

Stock-Based Compensation (Details 2) (USD $)	9 Months Ended
	Sep. 30, 2013
Options outstanding at January 1, 2013 - Number of Shares (in shares)	597,504
Granted - Number of Shares (in shares)	1,850
Exercised - Number of Shares (in shares)	0
Cancelled/Forfeited - Number of Shares (in shares)	-30,070
Expired - Number of Shares (in shares)	-14,906
Options outstanding at September 30, 2013 - Number of Shares (in shares)	554,378
Options exercisable at September 30, 2013 - Number of Shares (in shares)	484,582
Options outstanding - at January 1, 2013 Weighted Average Exercise Price (in dollars per share)	$13.03
Granted - Weighted Average Exercise Price (in dollars per share)	$7.15
Cancelled/Forfeited - Weighted Average Exercise Price (in dollars per share)	$14.61
Expired - Weighted Average Exercise Price (in dollars per share)	$15.98
Options outstanding at September 30, 2013 - Weighted Average Exercise Price (in dollars per share)	$12.84
Options exercisable at September 30, 2013 - Weighted Average Exercise Price (in dollars per share)	$12.89
Options outstanding at September 30, 2013 - Weighted Average Remaining Contractual Term (in years)	'4 years 10 months 24 days
Options exercisable at September 30, 2013 - Weighted Average Remaining Contractual Term (in years)	'4 years 6 months 11 days

StockBased_Compensation_Detail3

Stock-Based Compensation (Details Textual) (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Share Based Compensation Options Grants In Period Weighted Average Grant Date Fair Value	$8,687	$245,754
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures Rate	7.20%	7.50%

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	9 Months Ended
	Sep. 30, 2013
Nonvested, Number of Units at January 1, 2013	0
Granted, Number of Units	15,927
Vested, Number of Units	0
Cancelled/Forfeited, Number of Units	-2,951
Nonvested, Number of Units at September 30, 2013	12,976
Granted, Weighted Average Grant Date Fair Value	$7.40
Cancelled/Forfeited, Weighted Average Grant Date Fair Value	$7.40
Non-vested, Weighted Average Grant Date Fair Value at September 30, 2013	$7.40

Stockholders_Equity_Details_Te

Stockholders' Equity (Details Textual) (USD $)

1 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

12 Months Ended

9 Months Ended

Apr. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Aug. 31, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2012

Chief Financial Officer [Member]

Chief Financial Officer [Member]

Restricted Stock Units (RSUs) [Member]

Restricted Stock Units (RSUs) [Member]

Restricted Stock Units (RSUs) [Member]

Restricted Stock Units (RSUs) [Member]

Series B Preferred Stock [Member]

Series C1 Convertible Preferred Stock [Member]

Series C1 Convertible Preferred Stock [Member]

Series C Preferred Stock [Member]

Series C-1 Warrants [Member]

Convertible Preferred Stock Series C - 2 [Member]

Convertible Preferred Stock Series C - 2 [Member]

Convertible preferred stock, shares authorized

'

15,000,000

'

15,000,000

'

15,000,000

'

'

'

'

'

'

'

'

'

6,000

'

3,000

3,000

Preferred Stock and Warrant Purchase Agreement Warrants Authorized For Issuance To Acquire Common Stock Shares Number

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

272,263

'

'

'

Preferred Stock and Warrant Purchase Agreement Exercise Price Of Warrants Authorized

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$12.04

'

'

'

Stock Issued During Period, Value, Issued for Cash

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$6,000,000

'

'

'

Common stock issuable upon conversion of preferred stock

249,107

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock and Warrant Purchase Agreement, Warrants Issued To Acquire Common Stock Shares, Number

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

136,132

'

'

Proceeds from Issuance or Sale of Equity

'

'

'

'

'

'

'

'

'

'

'

'

'

3,000,000

'

'

'

'

'

Future Proceeds From Issuance Or Sale Of Equity

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,000,000

'

Payments of Stock Issuance Costs

'

'

'

'

'

'

'

'

'

'

'

'

'

334,000

'

'

'

'

'

Stock-based compensation

'

29,577

143,945

269,532

457,763

'

'

'

7,427

0

19,779

8,125

'

'

'

'

'

'

'

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Fair Value

'

'

'

'

'

'

'

117,861

'

'

'

'

'

'

'

'

'

'

'

Dividends on series B and C-1preferred stock

'

$251,333

'

$251,333

'

$125,333

'

'

'

'

'

'

$72,000

'

$179,333

'

'

'

'

Convertible preferred stock, shares issued

'

'

'

'

'

'

'

'

'

'

'

'

'

3,000

'

'

'

0

0

Stock Issued During Period, Shares, Restricted Stock Award, Gross

'

'

'

'

'

'

'

15,927

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total

'

'

'

'

'

'

2,951

'

'

'

'

'

'

'

'

'

'

'

'

Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grants In Period, Weighted Average Grant Date Fair Value

'

'

'

$7.40

'

'

'

$7.40

'

'

'

'

'

'

'

'

'

'

'

Derivative_Liabilities_Details

Derivative Liabilities (Details) (USD $)	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013
			Series B Warrant [Member]	Series B Warrant [Member]	Series B Warrant [Member]
					Chief Financial Officer [Member]
Series B warrants:	'	'	'	'	'
Risk-free interest rate	'	'	0.10%	0.22%	'
Expected volatility	'	'	62.28%	65.94%	'
Expected life (in years)	'	'	'	'1 year 8 months 8 days	'11 months 8 days
Expected dividend yield	'	'	0.00%	0.00%	'
Number of warrants	'	'	21,423	21,423	'
Fair value	$2,655	$57,610	$2,655	$15,950	'

Derivative_Liabilities_Details1

Derivative Liabilities (Details Textual) (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Derivative liabilities	$2,655	$57,610
Increase (Decrease) in Derivative Liabilities	$13,295	'

Loss_Per_Share_Details

Loss Per Share (Details)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,282,404	1,321,291
Convertible Preferred Stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	480,777	480,777
Warrant [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	233,753	242,534
Restricted Stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	12,976	0
Employee Stock Option [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	554,898	597,980

Concentration_of_Credit_Risk_D

Concentration of Credit Risk (Details Textual)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Customer 1 [Member]	'	'	'	'
Entity-Wide Accounts Receivable, Major Customer, Percentage	53.00%	43.00%	53.00%	43.00%
Concentration Risk, Percentage	36.00%	40.00%	45.00%	45.00%
Customer 2 [Member]	'	'	'	'
Entity-Wide Accounts Receivable, Major Customer, Percentage	15.00%	11.00%	15.00%	11.00%
Concentration Risk, Percentage	16.00%	11.00%	11.00%	10.00%
Customer 3 [Member]	'	'	'	'
Entity-Wide Accounts Receivable, Major Customer, Percentage	14.00%	'	14.00%	'
Concentration Risk, Percentage	14.00%	'	11.00%	'

Related_Party_Details_Textual

Related Party (Details Textual) (USD $)	1 Months Ended	3 Months Ended		9 Months Ended			9 Months Ended
	Apr. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Sep. 30, 2013	Sep. 30, 2013
		Merck Global Health Innovation Fund Llc [Member]	Merck Global Health Innovation Fund Llc [Member]	Merck Global Health Innovation Fund Llc [Member]	Merck Global Health Innovation Fund Llc [Member]	Merck Global Health Innovation Fund Llc [Member]	Series C-1 Preferred Stock [Member]	Series C-1 Warrants [Member]
Preferred Stock and Warrant Purchase Agreement Shares Issued	'	'	'	'	'	'	3,000	'
Preferred Stock and Warrant Purchase Agreement, Warrants Issued To Acquire Common Stock Shares, Number	'	'	'	'	'	'	'	136,132
Revenue from Related Parties	'	$34,736	$265,655	$164,171	$966,190	'	'	'
Accounts Receivable, Related Parties	'	$20,532	'	$20,532	'	$96,096	'	'
Common stock issuable upon conversion of preferred stock	249,107	'	'	'	'	'	'	'

Subsequent_Events_Details_Text

Subsequent Events (Details Textuals) (Subsequent Event [Member], Chief Executive Officer [Member], USD $)	9 Months Ended
	Sep. 30, 2013
Subsequent Event [Member] | Chief Executive Officer [Member]	'
Converse Company's Fee	$25,310
Separation Payment	$25,310
Stock Issued During Period Restricted Stock Vested	11,992